Literature DB >> 2686642

Affinity purification of the HIV-1 protease.

J C Heimbach1, V M Garsky, S R Michelson, R A Dixon, I S Sigal, P L Darke.   

Abstract

An inhibitor of the HIV-1 protease has been employed in the generation of a resin which allows the rapid purification of this enzyme. A peptide substrate analogue, H2N-Ser-Gln-Asn-(Phe-psi[CH2N]-Pro)-Ile-Val-Gln-OH, was coupled to agarose resin. The HIV-1 protease was expressed in E. coli and the supernatant from lysed cells was passed through the affinity resin. Active HIV-1 protease was then eluted with a buffer change to pH 10 and 2 M NaCl. Final purification to a homogeneous preparation, capable of crystallization, was achieved with hydrophobic interaction chromatography. Solutions containing HIV-1 protease bound to competitive inhibitors do not bind to the column.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686642     DOI: 10.1016/0006-291x(89)91762-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Production of cytotoxic proteins in Escherichia coli: a fermentation process for producing enzymatically active HIV-1 protease.

Authors:  W K Herber; F J Bailey; C E Carty; J C Heimbach; R Z Maigetter
Journal:  Appl Microbiol Biotechnol       Date:  1991-11       Impact factor: 4.813

2.  Affinity-based separations and purifications. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1991-01       Impact factor: 2.926

3.  3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV Protease.

Authors:  Wayne J Thompson; Arun K Ghosh; M Katharine Holloway; Hee Yoon Lee; Peter M Munson; John E Schwering; Jenny Wai; Paul L Darke; Joan Zugay; Emilio A Emini; William A Schleif; Joel R Huff; Paul S Anderson
Journal:  J Am Chem Soc       Date:  1993-01-01       Impact factor: 15.419

4.  Potent HIV-1 Protease Inhibitors: Stereoselective Synthesis of a Dipeptide Mimic.

Authors:  Arun K Ghosh; Sean P McKee; Wayne J Thompson; Paul L Darke; Joan C Zugay
Journal:  J Org Chem       Date:  1993-02       Impact factor: 4.354

5.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.

Authors:  R E Rose; Y F Gong; J A Greytok; C M Bechtold; B J Terry; B S Robinson; M Alam; R J Colonno; P F Lin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

6.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

Authors:  J P Vacca; B D Dorsey; W A Schleif; R B Levin; S L McDaniel; P L Darke; J Zugay; J C Quintero; O M Blahy; E Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Protein Sci       Date:  1992-10       Impact factor: 6.725

8.  Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease.

Authors:  C M Bechtold; A K Patick; M Alam; J Greytok; J A Tino; P Chen; E Gordon; S Ahmad; J C Barrish; R Zahler
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  CYCLIC SULFONE-3-CARBOXAMIDES AS NOVEL P2-LIGANDS FOR Ro 31-8959 BASED HIV-1 PROTEASE INHIBITORS.

Authors:  Arun K Ghosh; Wayne J Thompson; Peter M Munson; Wenming Liut; Joel R Huff
Journal:  Bioorg Med Chem Lett       Date:  2000-03-29       Impact factor: 2.823

10.  Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

Authors:  A K Patick; R Rose; J Greytok; C M Bechtold; M A Hermsmeier; P T Chen; J C Barrish; R Zahler; R J Colonno; P F Lin
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.